New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 26, 2024 - The FDA announced the approval of Bristol-Myers Squibb’s Cobenfy (xanomeline and trospium hydrochloride capsules) or the treatment of schizophrenia in adults.
Download PDF
Return to publications
